Abstract:Clotted plasma proteins are present on the walls of tumor vessels and in tumor stroma. Tumor-homing peptide Cys-Arg-Glu-Lys-Ala (CREKA) could recognize the clotted plasma proteins in tumor vessels. Thermosensitive liposomes could immediately release the encapsulated drug in the vasculature of the heated tumor. In this study, we designed a novel form of targeted thermosensitive liposomes, CREKA-modified lysolipid-containing thermosensitive liposomes (LTSLs), containing doxorubicin (DOX) (DOX-LTSL-CREKA), to investigate the hypothesis that DOX-LTSL-CREKA might target the clotted plasma proteins in tumor vessels as well as tumor stroma and then exhibit burst release of the encapsulated DOX at the heated tumor site. We also hypothesized that the high local drug concentration produced by these thermosensitive liposomes after local hyperthermia treatment will be useful for treatment of multidrug resistance. The multidrug-resistant human breast adenocarcinoma (MCF-7/ADR) cell line was chosen as a tumor cell model, and the targeting and immediate release characteristics of DOX-LTSL-CREKA were investigated in vitro and in vivo. Furthermore, the antitumor activity of DOX-LTSL-CREKA was evaluated in MCF-7/ADR tumor-bearing nude mice in vivo. The targeting effect of the CREKA-modified thermosensitive liposomes on the clotted plasma proteins was confirmed in our in vivo imaging and immunohistochemistry experiments. The burst release of this delivery system was observed in our in vitro temperature-triggered DOX release and flow cytometry analysis and also by confocal microscopy experiments. The antitumor activity of the DOX-LTSL-CREKA was confirmed in tumor-bearing nude mice in vivo. Our findings suggest that the combination of targeting the clotted plasma proteins in the tumor vessel wall as well as tumor stroma by using CREKA peptide and temperature-triggered drug release from liposomes by using thermosensitive liposomes offers an attractive strategy for chemotherapeutic drug delivery to tumors.

A novel tumor-targeted thermosensitive liposomal cerasome used for thermally controlled drug release.

Bubble-Manipulated Local Drug Release from a Smart Thermosensitive Cerasome for Dual-Mode Imaging Guided Tumor Chemo-Photothermal Therapy

Nanohybrid Liposomal Cerasomes with Good Physiological Stability and Rapid Temperature Responsiveness for High Intensity Focused Ultrasound Triggered Local Chemotherapy of Cancer.

Potent cancer therapy by liposome microstructure tailoring with active-to-passive targeting and shell-to-core thermosensitive features

Cypate-Mediated Thermosensitive Nanoliposome For Tumor Imaging And Photothermal Triggered Drug Release

Multifunctional Traceable Liposomes with Temperature-Triggered Drug Release and Neovasculature-Targeting Properties for Improved Cancer Chemotherapy

Improvement of Thermosensitive Liposome Stability by Cerasome Forming Lipid with Si-O-Si Network Structure

Novel Thermosensitive Polymeric Micelles for Docetaxel Delivery.

Thermosensitive Drug-loaded Liposomes for Photothermal and Chemotherapeutic Treatment of Colon Cancer

Cerasomal doxorubicin with long-term storage stability and controllable sustained release

Stable Cerasomes for Simultaneous Drug Delivery and Magnetic Resonance Imaging.

Paclitaxel controlled release system based on novel cerasome

The Antitumor Activity of Tumor-Homing Peptide-Modified Thermosensitive Liposomes Containing Doxorubicin on MCF-7/ADR: in Vitro and in Vivo.

Tumor Targeting Antibody-Conjugated Nanocarrier with Ph/thermo Dual-Responsive Macromolecular Film Layer for Enhanced Cancer Chemotherapy

Redox Responsive Liposomal Nanohybrid Cerasomes for Intracellular Drug Delivery.

Functionalized Thermoresponsive Micelles Self-Assembled from Biotin-Peg-B-P(Nipaam-Co-Hmaam)-B-Pmma for Tumor Cell Target

NIR-Triggered Thermosensitive Nanoreactors for Dual-Guard Mechanism-Mediated Precise and Controllable Cancer Chemo-Phototherapy.

Thermoresponsive and Substrate Self-Cycling Nanoenzyme System for Efficient Tumor Therapy

Quick-Responsive Polymer-Based Thermosensitive Liposomes for Controlled Doxorubicin Release and Chemotherapy.

Stabilized Liposomal Nanohybrid Cerasomes for Drug Delivery Applications

Tumor-specific delivery of gemcitabine with activatable liposomes